Leading cardiovascular device provider SMT (Sahajanand Medical Technologies Pvt. Ltd.) has successfully crossed 12,000 stent implants in the DACH region. SMT has achieved this growth in Switzerland, Austria, and Germany in less than a year since the product Supraflex Cruz was launched in this region.

DACH region has almost 50% share in terms of volume of Europe’s total coronary market of one million DES and has more than 650 Cath labs. This overwhelming positive response demonstrates great acceptability of Supraflex Cruz in some of the most prestigious and high-volume centers across Europe.

Cruz is quickly becoming the ‘DES of choice’ for challenging and complex cases because of its best-in-class and unmatched deliverability. Supraflex family stents have proved to be at par in safety and 61% numerically better in efficacy as compared to Abbott’s Xience* in an investigator initiated multicenter European randomized controlled trial with more than 1400 patients, called ‘TALENT‘. The findings of the TALENT trial were published in Lancet, world’s leading medical journal.

First implant of Cruz stent was performed by Prof. Dr. David Leistner at Charité Berlin Campus Benjamin Franklin. On the efficacy of Supraflex, Prof. Leistner says, “I am obviously convinced, the Supraflex Cruz family being a very attractive stent technology, which allows therapy for all phenotypes of CAD, including very complex lesions as well as anatomical challenging cases,” further he added, “Perfect Handling, impressive tractability combined with optimal radial force results in perfect PCI-results and that’s how an ‘all-rounder stent’ has to be.”

Speaking about the growth in the European region, Gaurav Goel, Head of Western Europe, SMT said, “This encouraging initial response clearly confirms that SMT has been able to help cardiologists in treating complex lesions through better deliverability of Cruz. DACH is one of the most advanced markets in Europe and SMT is gradually being recognized as a top tier player in the DES market.”

SMT believes in its philosophy of’ Pledged to Save Millions’ with every step in the direction of a healthy society. SMT has recently announced its entry into the structural heart valve market by acquiring Vascular Concepts Group.

*Supraflex is a registered trademark of SMT or its affiliates.
*Xience is a trademark or registered trademark of the Abbott Group of Companies.